• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Cost Savings More Important for Payer Committees than Clinical Concerns

Article

Pharmacy and therapeutic committees view potential cost savings as the most important factor when recommending formulary placement, according to a new survey.

With rising prescription drug prices challenging payers, how are their key decision makers adjusting their approach to recommending coverage for medicines?

A new survey finds that pharmacy and therapeutic committees, whose job it is to assess the clinical effectiveness of new drugs, view potential cost savings as the most important factor when recommending formulary placement. A formulary is a list of drugs that receive preferred coverage.

On a scale of one to six, potential cost savings of a drug ranked highest, at 3.8. This priority edged out the overall safety and efficacy of a drug relative to directly comparable medicines, at 3.7, according to the survey of P&T committees conducted by Barclays Bank analysts.

Read more at The Wall Street Journal: http://on.wsj.com/1H1vYkb

Related Videos
Dr Julie Patterson, National Pharmaceutical Council
Leslie Fish, PharmD.
James Robinson, PhD, MPH, University of California, Berkeley
James Robinson, PhD, MPH, University of California, Berkeley
James Robinson, PhD, MPH, University of California, Berkeley
Carrie Kozlowski
James Robinson, PhD, MPH, University of California, Berkeley
Carrie Kozlowski, OT, MBA
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Carrie Kozlowski, OT, MBA
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.